Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T Pipeline Into the Clinic
- Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical need
- Springboard Health Angels, Pluton Asset Holding AG, Sintra Limited, and Technologiegründerfonds Sachsen joined as new investors
- Existing investors i&i Biotech Fund I SCSp, HIL-INVENT and Brandenburg Kapital also participated in the round
Captain T Cell, a biotechnology company developing next-generation TCR-T cell therapies for solid tumors, today announced the successful closing of an equity financing round with both new and existing investors. The latest equity funding, along with already secured grants, provides Captain T Cell with a total budget of EUR 20 million to advance its best-in-class autologous program CTC127 to clinical Phase I read-outs and its first-in-class allogeneic program for off-the-shelf solid tumor treatments towards clinical trial readiness.
selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
- Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients
- si-544 is the first highly potent and selective Kv1.3 blocker to safely achieve patient plasma levels suitable for high target engagement
- Excellent safety and tolerability consistent with prior clinical experience; no dose-limiting toxicities and no serious safety signals observed
- Full immunocompetence maintained in si-544 treated patients; no immunosuppression
selectION, Inc. (“selectION” or the “Company”), a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, today announced the successful completion of its phase 1b proof-of-concept trial evaluating si-544, a first-in-class Kv1.3 blocker in patients diagnosed with psoriasis vulgaris.
ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
- Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers
- First-in-class multi-checkpoint inhibitor with robust efficacy and safety
- Combination arm with pembrolizumab (Keytruda®) in Australia near to completion by end 2025
ImmunOs Therapeutics AG, a clinical-stage biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and inflammatory diseases, today announced encouraging preliminary results from its ongoing Phase I clinical trial evaluating IOS-1002 in patients with advanced solid tumors.
